Embattled drugmaker Valeant Pharmaceuticals International Inc. offered tens of millions of dollars in incentives to a pharmacy to sell its products even as the relationship between the two was kept private, according to documents released by a Senate committee.
The 818 pages of documents, part of a trove reviewed by the Senate Special Committee on Aging before an April 27 hearing, provide new insights into a relationship that was at the heart of Valeant’s eventual share meltdown -- the drug maker’s financial arrangements with Philidor Rx Services, a nominally independent pharmacy that has since ceased operations.
The 818 pages of documents, part of a trove reviewed by the Senate Special Committee on Aging before an April 27 hearing, provide new insights into a relationship that was at the heart of Valeant’s eventual share meltdown -- the drug maker’s financial arrangements with Philidor Rx Services, a nominally independent pharmacy that has since ceased operations.
